Abstract
Introduction: Non-Small Cell Lung Cancer (NSCLC) is an aggressive malignancy with poor overall survival that accounts for up to 85% of lung cancer diagnoses. The use of immunotherapy in the form of checkpoint inhibition, to enhance the immune system’s ability to attack malignant cells, has been a promising addition to treatment options in advanced NSCLC.
Results: Such therapeutic agents aimed at the Programmed Death 1 (PD-1) receptor or Programmed Death Ligand 1 (PD-L1) have revealed promising results against many types of cancer including NSCLC. Examples of these agents include nivolumab, pembrolizumab, BMS-936559, atezolizumab, and MEDI4736, of which the first two are approved by US FDA in the second line treatment of advanced NSCLC.
Discussion: Impressive improvements in objective responses from PD-1 blockade were found in both first line therapy as well as treatment after progression on platinum based therapy. In addition, the safety profile is favorable with significantly lower grade 3-4 adverse events compared to standard of care. The optimal selection criteria and factors that show an increased response to therapy are still being determined.
Keywords: Immune Checkpoint Inhibitors, Non-Small-Cell Lung Cancer.
Reviews on Recent Clinical Trials
Title:Clinical Trials Investigating Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer
Volume: 11 Issue: 4
Author(s): Anshu Giri, Simrit S. Walia and Ajeet Gajra
Affiliation:
Keywords: Immune Checkpoint Inhibitors, Non-Small-Cell Lung Cancer.
Abstract: Introduction: Non-Small Cell Lung Cancer (NSCLC) is an aggressive malignancy with poor overall survival that accounts for up to 85% of lung cancer diagnoses. The use of immunotherapy in the form of checkpoint inhibition, to enhance the immune system’s ability to attack malignant cells, has been a promising addition to treatment options in advanced NSCLC.
Results: Such therapeutic agents aimed at the Programmed Death 1 (PD-1) receptor or Programmed Death Ligand 1 (PD-L1) have revealed promising results against many types of cancer including NSCLC. Examples of these agents include nivolumab, pembrolizumab, BMS-936559, atezolizumab, and MEDI4736, of which the first two are approved by US FDA in the second line treatment of advanced NSCLC.
Discussion: Impressive improvements in objective responses from PD-1 blockade were found in both first line therapy as well as treatment after progression on platinum based therapy. In addition, the safety profile is favorable with significantly lower grade 3-4 adverse events compared to standard of care. The optimal selection criteria and factors that show an increased response to therapy are still being determined.
Export Options
About this article
Cite this article as:
Giri Anshu, Walia S. Simrit and Gajra Ajeet, Clinical Trials Investigating Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer, Reviews on Recent Clinical Trials 2016; 11 (4) . https://dx.doi.org/10.2174/1574887111666160724181330
DOI https://dx.doi.org/10.2174/1574887111666160724181330 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Targeting of Cell Death Signal Transduction Pathways in Cancer
Current Signal Transduction Therapy Vascular Endothelial Growth Factor: A New Paradigm for Targeting Various Diseases
Current Angiogenesis (Discontinued) Patent Selections
Recent Patents on DNA & Gene Sequences Genetic and Epigenetic Signatures in Human Hepatocellular Carcinoma:A Systematic Review
Current Genomics NAMPT in Regulated NAD Biosynthesis and its Pivotal Role in Human Metabolism
Current Medicinal Chemistry Combining Oncolytic Virotherapy and Cytotoxic Therapies to Fight Cancer
Current Pharmaceutical Design Cancer Control by Phytochemicals
Current Pharmaceutical Design Immunostimulatory Oligonucleotides
Recent Patents on Inflammation & Allergy Drug Discovery Editorial: (Thematic Issue: Occupational Exposure: An Undermined Risk Factor of Lung Diseases in the Informal Sectors of Developing Economy)
Current Respiratory Medicine Reviews Synthesis and Anti Lung Cancer Activity of 3-Arylspiro[oxirane-2,3'- thiochroman]-4'-one Derivatives
Letters in Organic Chemistry GRAPHICAL ABSTRACTS
Letters in Drug Design & Discovery Dry Powder Formulation of Plasmid DNA and siRNA for Inhalation
Current Pharmaceutical Design Functions of MAPR (Membrane-Associated Progesterone Receptor) Family Members As Heme/Steroid-Binding Proteins
Current Protein & Peptide Science Vandetanib, A Dual Inhibitor of VEGFR and EGFR Tyrosine Kinase Activity
Current Cancer Therapy Reviews Effects of Plants and Isolates of Celastraceae Family on Cancer Pathways
Anti-Cancer Agents in Medicinal Chemistry ANTI-ADHESION Evolves To a Promising Therapeutic Concept in Oncology
Current Medicinal Chemistry Recombinant Human Serum Albumin Fusion Proteins and Novel Applications in Drug Delivery and Therapy
Current Pharmaceutical Design Latest Results for Anti-Angiogenic Drugs in Cancer Treatment
Current Pharmaceutical Design The Need for Calcium Channels in Cell Proliferation
Recent Patents on Anti-Cancer Drug Discovery ATP-Binding Cassette Efflux Transporters in Human Placenta
Current Pharmaceutical Biotechnology